Thoracic Surgery Devices Market Size & Share 2026-2035

Thoracic Surgery Devices Market Size

The thoracic surgery devices market was valued at USD 815 million in 2025 and is projected to reach USD 871 million in 2026, expanding at a CAGR of 6.9% from 2026 to 2035, to reach USD 1.58 billion by 2035.

The thoracic surgery devices market encompasses instruments, accessories, and disposables used in open thoracotomy, video-assisted thoracoscopic surgery (VATS), and robotic-assisted thoracic surgery (RATS), while excluding capital robotic system hardware. Its evolution is being shaped by the transition toward minimally invasive resection, which increases per-case use of disposable and platform-compatible instruments relative to reusable open-surgery sets. Screening-led diagnosis, broader robotic program deployment, and outpatient migration are reinforcing demand across distinct care settings.

Thoracic Surgery Devices Market Trends, Growth Drivers & GMI Forecast Outlook

Thoracic device demand is being reshaped by the convergence of earlier lung cancer detection, minimally invasive procedural adoption, and new robotic platform capabilities. Growth depends not only on resection volume, but also on the instrument mix used in each case, the pace of surgeon training, and the affordability of premium disposable configurations across health systems.

Key Drivers

Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.

Lung cancer remains the most frequently diagnosed malignancy worldwide and the leading cause of cancer mortality, creating a sustained clinical foundation for thoracic intervention demand ^{[1]Bray F, Laversanne M, Sung H, et al. "Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries." wiley.com}. Screening programs can increase the identification of earlier-stage lesions that are more suitable for wedge resection, segmentectomy, and minimally invasive lobectomy. These procedures require multiple instrument types across dissection, vessel control, tissue division, and specimen handling, supporting consumable intensity as surgical eligibility expands.

Technique conversion is equally important to market value creation. A review of Society of Thoracic Surgeons data found that more than 80% of lobectomies, segmentectomies, and wedge resections in the United States were performed using minimally invasive approaches ^{[2]PubMed Central / National Library of Medicine. "Advancements in Video-Assisted Thoracoscopic Surgery and Robotic-Assisted Thoracic Surgery." nih.gov}. VATS and RATS replace portions of the reusable open-surgery workflow with specialized endoscopic and robotic-compatible instruments, creating repeat demand for staplers, graspers, scissors, ports, and related accessories.

Robotic platform commercialization further strengthens this recurring-revenue mechanism. The da Vinci 5 introduces Force Feedback technology and has a general thoracoscopic indication, extending the relevance of robotic workflows for complex thoracic programs ^{[5]Intuitive Surgical, Inc. "Annual Report 2024." sec.gov}. As hospitals replace aging platforms or introduce robotics into additional service lines, instrument demand is likely to be determined increasingly by installed-base utilization and surgeon credentialing rather than by initial capital placement alone.

Key Restraints

Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.

Specialist availability is a practical limitation on how quickly infrastructure investment can translate into procedure volume. The Society of Thoracic Surgeons notes that approximately 900 cardiothoracic surgeons are expected to retire while demand for the specialty is projected to increase by 20% ^{[4]Society of Thoracic Surgeons. "Advocacy Issue: Physician Workforce." sts.org}. This gap is especially consequential in markets where new operating capacity is being added faster than training pathways, proctorship networks, and multidisciplinary thoracic teams.

Clinical preference is also changing the economic profile of thoracic care. The narrowing role of pneumonectomy favors lung-sparing procedures that use different combinations of stapling, precision dissection, and access instruments. Manufacturers concentrated in large, open-procedure configurations may face a more selective demand environment, whereas suppliers with broad minimally invasive portfolios can participate in the changing procedure mix.

Regulatory documentation and premium accessory pricing create additional friction. Product modifications may require fresh submissions or technical-file updates, increasing the burden of maintaining extensive instrument portfolios. In cost-sensitive hospital systems, procurement committees may defer premium robotic accessory adoption even when clinical teams recognize their workflow advantages.

Thoracic Surgery Devices Market Segment Analysis

By Product

Staplers

Staplers generated USD 285 million in 2025 and represented 35.0% of the global market. The category remains fundamental to bronchial transection, vascular division, and parenchymal closure in thoracic resection. Its scale reflects broad use across open, VATS, and robotic procedures, although expanding adoption of accessory-intensive robotic configurations is expected to diversify the overall product mix.

Forceps held a 12.0% share of the market in 2025 and are projected to generate USD 175 million by 2035. Dissecting, grasping, and tissue-handling forceps are used through multiple stages of thoracic procedures. Robotic wristed designs are commercially important because platform compatibility and ergonomic precision can make them a recurring component of the per-case instrument set.

Clamps

Clamps generated USD 82 million in 2025 and are expected to account for a 9.0% share of the market by 2035. Demand remains linked to open and hybrid procedures requiring vessel, bronchial, or tissue occlusion. Their relative position is affected by the migration toward VATS and RATS, where endoscopic stapling and other minimally invasive alternatives reduce reliance on conventional clamp configurations.

Graspers

Graspers accounted for a 9.0% share of the market in 2025 and are projected to reach USD 159 million by 2035. Growth is supported by the precision requirements of minimally invasive lobectomy and segmentectomy. Robotic-compatible graspers can command recurring demand because their articulating designs and attachment specifications are closely tied to a platform's clinical workflow.

Scissors

Scissors represented 8.0% of market revenue in 2025 and are projected to generate USD 127 million by 2035. Endoscopic, hook, and Maryland-style scissors remain necessary for mediastinal dissection, adhesiolysis, and vessel preparation. Demand is supported by higher procedural complexity in minimally invasive programs and by infection-control preferences that favor single-use or replaceable cutting components.

Spreaders & Retractors

Spreaders & Retractors held a 7.0% share of the market in 2025 and are forecast to expand at a CAGR of 8.3% from 2026 to 2035. The category benefits from the need to maintain exposure through smaller access points. Low-profile and procedure-specific retraction systems are increasingly relevant in robotic and advanced VATS cases, particularly where hilar and mediastinal anatomy requires stable visualization without broad thoracotomy access.

Needle Holders

Needle Holders generated USD 41 million in 2025 and are projected to reach USD 79 million by 2035. Their demand is concentrated in procedures involving intracorporeal suturing, reconstruction, and vessel repair. Wristed and articulated designs are gaining importance as thoracic surgeons perform more complex maneuvers through constrained minimally invasive access routes.

Other Products

Other Products generated USD 114 million in 2025 and are expected to represent 16.0% of market revenue by 2035. This category includes trocars, ports, lung retractors, drainage instruments, bronchial blockers, and other procedural accessories. Its increasing relevance reflects the growing number of single-use components required to support standardized VATS and robotic procedure pathways.

By Surgery Type

Lobectomy

Lobectomy generated USD 342 million in 2025 and represented 42.0% of the market. The procedure requires a broad instrument set spanning tissue division, vessel management, retraction, dissection, and closure. Its commercial importance is reinforced by its central role in the treatment of surgically resectable lung cancer and by the continuing conversion of lobectomy from open surgery to VATS and robotic techniques.

Wedge Resection

Wedge Resection accounted for 32.0% of market revenue in 2025 and is projected to generate USD 524 million by 2035. Its shorter operating time and suitability for peripheral lesions, biopsies, and selected early-stage cancers support adoption in high-throughput minimally invasive settings. The procedure is also closely associated with outpatient migration, where standardized disposable kits can simplify procurement and operating-room preparation.

Pneumonectomy

Pneumonectomy generated USD 106 million in 2025 and is expected to represent 10.0% of the market by 2035. Although individual cases remain instrument-intensive, clinical practice increasingly reserves complete lung removal for highly selective indications. The shift toward lung-sparing alternatives changes demand toward more precision-oriented minimally invasive configurations rather than eliminating the need for specialized thoracic instruments.

Other Surgery Types

Other Surgery Types represented 13.0% of the market in 2025 and are projected to reach USD 222 million by 2035. This category includes segmentectomy, decortication, pleurodesis, thymectomy, esophageal procedures, and chest wall interventions. Its growth is supported by widening minimally invasive indications and the expanding use of robotic platforms in anatomically complex thoracic applications.

By End Use

Hospitals

Hospitals generated USD 530 million in 2025 and represented 65.0% of market revenue. Hospitals remain the core purchasing channel because many thoracic resections require specialist anesthesia, lung isolation, postoperative monitoring, and access to intensive care. Large academic and integrated health-system programs also shape vendor selection through preference cards, formal contracting, and demand for clinical support.

Ambulatory Surgery Centers

Ambulatory Surgery Centers accounted for 28.0% of market revenue in 2025 and are projected to generate USD 524 million by 2035. The channel is gaining relevance for selected minimally invasive wedge resections and lower-complexity thoracic cases. Its procurement model favors standardized, reproducible disposable configurations, creating a favorable setting for suppliers that can combine clinical efficiency with predictable per-procedure cost.

Other Healthcare Facilities

Other Healthcare Facilities generated USD 57 million in 2025 and are projected to reach USD 111 million by 2035. This channel includes specialty outpatient sites, teaching facilities, and hybrid care settings. Demand is shaped by diagnostic interventions, education and training activity, and the gradual extension of specialist procedural capability beyond traditional hospital and ambulatory surgery center classifications.

Thoracic Surgery Devices Market Regional Analysis

North America Thoracic Surgery Devices Market Analysis

The thoracic surgery devices market in North America generated USD 326 million in 2025 and represented 40.0% of global revenue. The region's leadership reflects deep penetration of VATS, a substantial installed base of robotic surgical systems, and concentrated specialist expertise at academic and integrated delivery networks. Contracting discipline is high, but sustained robotic utilization, community-hospital technique conversion, and outpatient resection pathways continue to support instrument demand.

U.S.

The U.S. generated USD 284 million in 2025 and is projected to reach USD 511 million by 2035. The country is the principal source of regional demand because established thoracic programs combine high minimally invasive utilization with broad access to advanced stapling, visualization, and robotic accessories. Group purchasing organizations and integrated delivery networks influence purchasing decisions, favoring suppliers that can provide portfolio breadth and procedural support.

Europe Thoracic Surgery Devices Market Analysis

The thoracic surgery devices market in Europe accounted for a 24.9% share of global revenue in 2025 and is projected to generate USD 365 million by 2035. European demand is differentiated by mature VATS programs in Western European systems and more budget-constrained procurement environments in parts of Southern and Eastern Europe. The region's opportunity rests on continued robotic adoption at high-volume centers, alongside the gradual expansion of screening and surgical capacity across national healthcare systems.

Asia Pacific Thoracic Surgery Devices Market Analysis

The thoracic surgery devices market in Asia Pacific generated USD 212 million in 2025 and is expected to represent 30.0% of global revenue by 2035. The region combines mature minimally invasive ecosystems in Japan and South Korea with broad first-cycle VATS conversion in China and India. This creates demand across the instrument spectrum, from foundational staplers and ports to robotic-compatible accessories, while hospital investment and specialist training determine the pace at which new capacity becomes productive.

China

China generated USD 74 million in 2025 and is projected to expand at a CAGR of 9.4% from 2026 to 2035. Tier-2 and Tier-3 hospital conversion to VATS is widening the customer base for thoracic instrument sets. Initial procurement is likely to remain weighted toward staples, basic access devices, and conventional endoscopic tools before robotic adoption becomes more widespread across provincial hospital networks.

Japan

Japan generated USD 59 million in 2025 and is projected to reach USD 124 million by 2035. Japan's mature VATS ecosystem provides a stable foundation for recurring disposable demand. The national registry recorded 85,067 VATS procedures in 2024, representing 90% of general thoracic procedures and a 5.9% year-over-year increase ^{[3]Japanese Association for Thoracic Surgery / National Clinical Database. "Thoracic and cardiovascular surgeries in Japan during 2024." springer.com}. Continued platform upgrades at university hospitals and oncology networks should further enrich the instrument mix.

India

India generated USD 38 million in 2025 and is projected to expand at a CAGR of 9.6% from 2026 to 2035. Government-backed healthcare investment and the extension of surgical infrastructure into secondary cities are expanding access to thoracic care. Market development depends on the parallel availability of trained teams, reliable distributor coverage, and procurement models that can accommodate minimally invasive procedure requirements.

South Korea

South Korea generated USD 21 million in 2025 and is projected to reach USD 48 million by 2035. The country's advanced minimally invasive thoracic practice and growing robotic procedure base support demand for sophisticated disposable instruments. Screening activity and increasing use of sub-lobar resection are also reinforcing the need for precision-focused procedural configurations.

Latin America Thoracic Surgery Devices Market Analysis

The thoracic surgery devices market in Latin America accounted for a 4.8% share of global revenue in 2025 and is projected to expand at a CAGR of 7.3% from 2026 to 2035. Brazil and Mexico provide the primary demand base, supported by private hospital networks and selected public oncology investments. Growth is likely to be uneven because budget constraints, reimbursement variation, and specialist availability influence the pace of VATS and robotic program adoption across national markets.

Middle East & Africa Thoracic Surgery Devices Market Analysis

The thoracic surgery devices market in Middle East & Africa generated USD 35 million in 2025 and is expected to represent 5.0% of global revenue by 2035. Regional growth is tied to hospital construction, specialist recruitment, and the development of tertiary surgical services in Saudi Arabia and the UAE, with South Africa providing an additional private-sector base. Suppliers with practical training resources, distributor reach, and flexible product configurations are likely to be more relevant than those focused only on premium robotics-linked portfolios.

Thoracic Surgery Devices Market Share & Competitive Landscape

The thoracic surgery devices market share is concentrated among large medical technology companies with established positions in robotic accessories, endoscopic stapling, visualization, and procedural consumables. Competition centers on platform compatibility, hospital contracting, clinical education, product breadth, and the ability to support surgeons across open, VATS, and robotic workflows. The 18.6% share held by other participants in 2025 also indicates meaningful competitive depth below the leading companies.

Intuitive Surgical

Intuitive Surgical held a 23.6% market share in 2025. Its position is underpinned by the recurring instruments-and-accessories demand associated with the da Vinci installed base. By year-end 2024, the company had placed 362 da Vinci 5 systems in the United States, while more than 2,500 surgeons had performed more than 32,000 procedures using the platform ^{[5]Intuitive Surgical, Inc. "Annual Report 2024." sec.gov}. The commercial advantage lies in the tight linkage between system utilization, surgeon workflows, and procedure-specific disposable consumption.

Medtronic

Medtronic held a 20.7% market share in 2025. The company's endoscopic stapling franchise, open and hybrid thoracic instruments, and robotic surgery initiative position it across several areas of demand. Its ability to pair consumables with clinical training and broad hospital relationships is important in accounts that are expanding VATS capabilities while evaluating future robotic workflows.

J&J MedTech / Ethicon

J&J MedTech / Ethicon held an 18.7% market share in 2025. Its market standing is supported by embedded use of stapling, energy, and cutting technologies in established thoracic preference cards. A broad consumables portfolio helps the company retain relevance across lobectomy and wedge resection workflows, particularly where institutions value standardization and long-standing clinical familiarity.

Karl Storz

Karl Storz generated USD 64 million in thoracic surgery device revenue in 2025. The company's thoracoscopic visualization systems, optics, and digital operating-room capabilities complement its instrument presence. Its acquisition of T1V's medical business added the CollaboratOR clinical collaboration platform, strengthening its strategy to connect visualization hardware with workflow and data-management capabilities ^{[7]KARL STORZ. "KARL STORZ Acquires Medical Business of Visual Collaboration Software Company T1V." businesswire.com}.

Olympus

Olympus held a 4.4% market share in 2025. Olympus participates through thoracoscopy, bronchoscopy, and visualization technologies, while its move into preoperative planning extends its relevance beyond the operating room. The company's REVORAS platform uses artificial intelligence to convert imaging data into three-dimensional anatomical models intended to support planning for lung cancer surgery and complex segmentectomy ^{[6]Olympus Corp. of the Americas. "Olympus Announces Launch of AI-Powered Surgical Planning Tool Through Strategic Partnership with Ziosoft." olympusamerica.com}.

B. Braun maintains a focused presence in open and hybrid thoracic instruments, while ConMed participates in visualization and energy applications. Fujifilm Holdings contributes through bronchoscopy and imaging platforms relevant to diagnostic staging. Boston Scientific, Cook Medical, Cardinal Health, GE Healthcare, Biolitec, Medela, and MicroPort serve specialized positions across procedural supplies, imaging, drainage, and related thoracic care requirements.

Recent Industry Developments

January 8, 2025 - KARL STORZ acquires T1V medical business

KARL STORZ acquired T1V's medical business, including its CollaboratOR portfolio, related intellectual property, and medical team ^{[7]KARL STORZ. "KARL STORZ Acquires Medical Business of Visual Collaboration Software Company T1V." businesswire.com}. The acquisition supports Karl Storz's effort to integrate real-time data collaboration, imaging access, and digital workflow tools with its operating-room visualization offering.

March 12, 2025 - Olympus launches REVORAS through its Ziosoft partnership

Olympus announced the commercial launch of REVORAS, an artificial intelligence-powered surgical planning tool developed with Ziosoft ^{[6]Olympus Corp. of the Americas. "Olympus Announces Launch of AI-Powered Surgical Planning Tool Through Strategic Partnership with Ziosoft." olympusamerica.com}. The platform creates real-time three-dimensional anatomical models from CT and MRI data, supporting preoperative planning for lung cancer procedures, including complex segmentectomies.